Results 171 to 180 of about 60,395 (277)

Novel clinical indenoisoquinoline topoisomerase I inhibitors: a twist around the camptothecins. [PDF]

Oncotarget, 2018
Pommier Y, Cushman M, Doroshow JH.
europepmc   +1 more source

Carcinogenic Medications: A Review of Specific Agents and Molecular Mechanisms of Carcinogenesis

Cancer Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background Pharmacovigilance has revealed an alarming correlation between certain medications and a higher risk of cancer. In this narrative review, included research from 2020 to 2025, along with a few seminal older studies, so that it provides a clear picture of which drugs actually set off cancer and mechanisms involved at the molecular ...
Desta Seyoum Tadesse, Kalkidan Tekletsadik, Berhan Begashaw, Awgichew Shewasinad Yehualashet, Awol Mekonnen Ali, Kassahun Dires Ayenew   +5 more
wiley   +1 more source

Unveiling the Anticancer Potential: Computational Exploration of Nitrogenated Derivatives of (+)-Pancratistatin as Topoisomerase I Inhibitors. [PDF]

Int J Mol Sci
Mohamed MA, Elsaman T, Elderdery AY, Alsrhani A, Ghanem HB, Alruwaili MM, Hamza SMA, Mekki SEI, Alotaibi HA, Mills J.   +9 more
europepmc   +1 more source

Hemophagocytic Lymphohystiocytosis in a Patient With Suspected Acute Myeloid Leukemia and Recent Viral Illness Compatible With Dengue: A Case Report and Literature Review

Cancer Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background Hemophagocytic lymphohistiocytosis, or HLH, is a very rare and aggressive disorder of the immune system, for which the trigger may be an infection, malignancy, or autoimmune disease. It has predominantly been described as triggered by T/NK lymphomas, but acute myeloid leukemia‐induced HLH is a very rare occurrence.
Halima Saleh, Sariya Khan, Huda Albraim, Sahar Albraim, Amatul Rafey, Mable Pereira, Tarek Mohammed   +6 more
wiley   +1 more source

Pursuing Polypharmacology: Benzothiopyranoindoles as G-Quadruplex Stabilizers and Topoisomerase I Inhibitors for Effective Anticancer Strategies. [PDF]

ACS Med Chem Lett
Salerno S, Barresi E, Roggia M, Natale B, Marzano S, Hyeraci M, Reina SCR, Baglini E, Amato J, Salvati E, Dalla Via L, Da Settimo F, Cosconati S, Taliani S.   +13 more
europepmc   +1 more source

Optimizing Body Size‐Based Dosing Approaches for Antibody–Drug Conjugates

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 872-880, April 2026.
Optimized dosing precision of antibody–drug conjugates (ADCs) remains challenging due to narrow therapeutic indices, efficacious doses near the maximum tolerated dose, and substantial interindividual variability in exposure. Body size‐based dosing can reduce exposure variability when the allometric scaling exponent for clearance α = 1 but may over‐ or ...
Andrew B. SyBing, Diane D. Wang
wiley   +1 more source

Antiplasmodial Activity and Pharmacokinetic Profiling of Cryptolepine and 2,7‐Dibromocryptolepine With a View to Informing the Design of Novel Antimalarial Cryptolepine Analogues

Drug Development Research, Volume 87, Issue 2, April 2026.
ABSTRACT The roots of the climbing shrub Cryptolepis sanguinolenta are traditionally used in West Africa for the treatment of malaria. The principal constituent, cryptolepine (1), has been shown to have antimalarial activity but there are concerns regarding its toxicity on account of its DNA‐intercalating property.
Elodie Chenu, James Duffy, Arnold Donkor Forkuo, Stephen Y. Gbedema, Seham Abdelall, Muhammad Wahajuddin, Huw S. Jones, Colin W. Wright   +7 more
wiley   +1 more source

New Benzimidazole-Triazole Derivatives as Topoisomerase I Inhibitors: Design, Synthesis, Anticancer Screening, and Molecular Modeling Studies. [PDF]

ACS Omega
Çevik UA, Kaya B, Celik I, Rudrapal M, Rakshit G, Karayel A, Levent S, Osmaniye D, Sağlık Özkan BN, Baysal M, Atlı Ekliog Lu Ö, Özkay Y, Kaplancıklı ZA.   +12 more
europepmc   +1 more source

Machine Learning Models Combined with Virtual Screening and Molecular Docking to Predict Human Topoisomerase I Inhibitors. [PDF]

Molecules, 2019
Li B, Kang X, Zhao D, Zou Y, Huang X, Wang J, Zhang C.   +6 more
europepmc   +1 more source

A LAT1‐Compatible, Leadlike Tyrosine‐Naphthoquinone Conjugate With Anticancer Activity

Drug Development Research, Volume 87, Issue 2, April 2026.
ABSTRACT A L‐type amino acid transporter 1 (LAT1)‐compatible, anticancer‐active tyrosine‐naphthoquinone (NQ) conjugate was successfully developed. The conjugate was designed to exploit LAT1 overexpression in cancers with the goal of achieving selective cytotoxicity for cancerous over noncancerous cells.
Austin Seymour, Christian Peterson, Raymond Osafo, Abdullahi A. Ashimi, Dylan Williams, Laura Echezabal, Chelsea Carrier, Alysa Clarke, Clifford W. Padgett, Mark Vincent C. dela Cerna, Zheni Utic, Divine Wanduku, Nathaniel Shank, Karelle S. Aiken, Jannet Kocerha   +14 more
wiley   +1 more source